Since the pionneer work of Meerwaldt and the Groningen team, who related skin autofluorescence (SAF) to the dermal concentrations of advanced glycation end-products (AGEs), hundreds of articles have been devoted to its application in diabetes. Due to the slow turnover of the AGEs formed on collagen of the skin, the SAF can reflect the progressive accumulation of AGEs and hence be a marker of long-term glucose exposure. Accordingly, relations with HbA1c from the previous 3-10 years have been established in both type 1 and type 2 diabetes, and even in gestational diabetes mellitus. Other important determinants of SAF exist however, notably age, renal function, diet, and genetics. SAF is also related to current and future micro- and macrovascular complications of diabetes, as expected for a marker of glycemic memory. It is also related to some important emerging diabetes complications and comorbidities such as cancer, cognitive decline and liver disease. Quantitative information on glucose exposure during the previous years may be pertinent to personnalize care for patients with diabetes: priority for glucose control when SAF is low, and for screening for complications once SAF is high.